Perceptive Imaging, a global leader in clinical trial imaging solutions for the clinical research community, announced the appointment of Doug Fulling as Chief Executive Officer, succeeding David Herron, who led the company since 2022. Fulling officially assumed his new role on October 1st and will spearhead the company’s growth strategy, focused on enhancing client services, expanding capacity, and developing innovative imaging technologies to support clinical development objectives. Herron will continue with the business in a Board of Directors role.
Doug Fulling brings more than 25 years of executive leadership and business development experience in the life sciences sector. He previously served as President of Precision AQ (part of Precision Medicine Group) and President of Symphony Health (an ICON Plc company), alongside senior leadership roles at PRA Health Sciences and MDS Pharma Services. His experience spans scaling organizations, driving innovation, and cultivating strong client relationships across the industry.
Perceptive Imaging’s customer-centric operating model has delivered substantial business growth, a robust pipeline of upcoming studies, and continued trust from leading pharmaceutical companies. Its reputation among the Top 20 pharma companies has enabled the company to secure multiple renewed mandates and support nearly 400 regulatory approvals as of June 30, 2025.
“Perceptive Imaging has undergone significant transformation in recent years and is strongly positioned to embark on the next chapter of the company’s development,” said Doug Fulling. “I have followed the company’s evolution for more than a decade and am honored to join the team at such an exciting time. I look forward to working with my colleagues and clients to deliver imaging solutions that accelerate bringing new medical treatments to patients. We thank David Herron for his leadership in transforming Perceptive into a highly sophisticated healthcare platform with promising future prospects.”
David Herron added:
“We are very pleased to appoint an executive of Doug Fulling’s caliber to lead Perceptive Imaging. His extensive experience and proven track record in scaling organizations, combined with our team’s expertise and dedication, position Perceptive to achieve its ambitious goals. I am proud of what we have accomplished together and excited for the next phase under Doug’s leadership. I look forward to supporting him as a Board member to drive innovation and foster new strategic partnerships that ensure long-term success for Perceptive and its clients.”
Under Fulling’s leadership, Perceptive Imaging aims to:
- Enhance client services to meet evolving clinical trial demands
- Expand capacity and operational efficiency for upcoming global studies
- Develop innovative imaging technologies to accelerate clinical research
- Strengthen strategic partnerships with pharmaceutical and biotech clients
Perceptive Imaging’s commitment to high-quality, regulatory-compliant imaging services has solidified its position as a trusted partner for pharmaceutical companies worldwide. With the leadership transition, the company is poised to scale its capabilities, expand global reach, and continue supporting the development of innovative therapies for patients.
The appointment of Doug Fulling marks a key milestone in Perceptive Imaging’s evolution, reinforcing the company’s mission to provide exceptional imaging solutions while driving innovation, operational excellence, and sustainable growth in the clinical research sector.
